Translation-X funding news – Basel-based Translation-X Secures €160k from Venture Kick

With few therapies for the primary symptoms of autism spectrum disorders (ASD), which frequently involve difficulties with social contact, these conditions represent a serious gap in medical care. The poor understanding of the underlying biological causes of ASD is a major obstacle to the development of effective therapeutics.

The designation of these therapies as orphan drugs may be advantageous, offering a planned market introduction as well as a basis for future growth. The company is primarily investigating selective mRNA translation as a possible medicinal method. With a special emphasis on Map-kinase interacting kinases (MNK) as a potential therapeutic target, their research has revealed dysregulated mRNA translation as a fundamental problem in a subgroup of ASD.

Read also - xtype funding news – Austria-based xtype Secures €19 Million in Series A Round Funding

It targets a genetically specified subgroup of autism and offers a promising treatment that directly targets the underlying pathology of the condition by suppressing MNK and restoring normal mRNA translation and neuronal function.

In order to get funding, get input straight from the source, and connect with 200 successful investors and entrepreneurs worldwide, startups present their ideas to expert judges in three rounds. Venture Kick winners can get a CHF 150,000 InnoBooster award as well as an additional CHF 850,000 from the Kickfund.

Özgür Genç said, “Venture Kick helped us better understand the business challenges of the startup world. Throughout the three stages, we benefited from its structured approach which helped to focus on essential business tasks like defining the business model and preparing for investment readiness,” highlighted. It also introduced us to key experts and networks, opening valuable opportunities for us.”

The drug development project will be accelerated from the hit to the lead stage with the help of the Venture Kick money.

About Translation-X

Translation-X is an independent initiative at the University of Basel's Biozentrum. RNA translational machinery is the target of new pharmaceutical strategies that they are developing to alleviate key symptoms of autism.